Loading...
•
Dec 31, 2022
Eagle Q4 2022 Earnings Report
Eagle Pharmaceuticals reported Q4 2022 results with increased revenue and net income.
Key Takeaways
Eagle Pharmaceuticals reported a strong Q4 2022, with a significant increase in total revenue to $60.7 million compared to $42.3 million in Q4 2021. Net income for the quarter was $8.2 million, a substantial improvement from the net loss of $(6.2) million in the same quarter of the previous year. The company's success was driven by growth in product sales, including PEMFEXY, and effective management of its bendamustine franchise.
Q4 2022 net income was $0.63 per basic and $0.62 per diluted share, while adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share.
Total revenue for Q4 2022 reached $60.7 million, up from $42.3 million in Q4 2021.
Net sales of PEMFEXY® totaled $12.1 million in Q4 2022.
Eagle had $55.3 million in cash and cash equivalents as of December 31, 2022.
Eagle
Eagle
Eagle Revenue by Segment
Revenue by Segment
BELRAPZO product sales Revenue
CapyFin.comRYANODEX product sales Revenue
CapyFin.com Forward Guidance
Eagle Pharmaceuticals anticipates growth in Barhemsys and Byfavo, intends to manage its U.S. bendamustine franchise, support Enalare’s development of ENA-001, and advance its pipeline programs for CAL02 and landiolol. The company's strong cash position and balance sheet provide flexibility to support clinical development and seek acquisitions.
Positive Outlook
- Anticipate growth in Barhemsys and Byfavo.
- Intend to continue managing the U.S. bendamustine franchise.
- Support Enalare’s development of ENA-001.
- Advance pipeline programs for CAL02 and landiolol.
- Strong cash position and balance sheet provide flexibility for clinical development and acquisitions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income